BRAF inhibitor activity in V600R metastatic melanoma-Reference-Cited by-同舟云学术

BRAF inhibitor activity in V600R metastatic melanoma

Published:2013-03 Issue:5 Volume:49 Page:1073-1079
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Klein Oliver,Clements Arthur,Menzies Alexander M.,O’Toole Sandra,Kefford Richard F.,Long Georgina V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. From genes to drugs: targeted strategies for melanoma;Flaherty;Nat Rev Cancer,2012

2. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma;Long;J Clin Oncol,2011

3. NRAS mutation status is an independent prognostic factor in metastatic melanoma;Jakob;Cancer,2011

4. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma;Thomas;Cancer Epidemiol Biomarkers Prev,2007

5. Catalogue of Somatic Mutations in Cancer (COSMIC) Website. Wellcome Trust Sanger Institute. Available from: http://www.sanger.ac.uk./genetics/CGP/cosmic.

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?;The Cancer Journal;2024-03

2. Synthesis and evaluation of 18F-labeled procainamide as a PET imaging agent for malignant melanoma;Bioorganic & Medicinal Chemistry Letters;2023-11

3. Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma;Journal of Pharmaceutical Policy and Practice;2023-09-25

4. Combination of the natural product mensacarcin with vemurafenib (Zelboraf) combats BRAF mutant and chemo-resistant melanoma in vitro by affecting cell metabolism and cellular migration;Advances in Cancer Biology - Metastasis;2022-12

5. Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort;JCO Precision Oncology;2022-11